Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
5.29
+0.54 (11.37%)
At close: Mar 28, 2025, 4:00 PM
5.44
+0.15 (2.84%)
After-hours: Mar 28, 2025, 7:59 PM EST

Serina Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.063.150.593.46
Revenue Growth (YoY)
-98.22%433.05%-82.93%-
Cost of Revenue
7.482.391.573.8
Gross Profit
-7.420.77-0.98-0.33
Selling, General & Admin
8.152.31.291.3
Operating Expenses
8.152.31.291.3
Operating Income
-15.57-1.53-2.27-1.63
Interest Expense
-0.53-0.56-0.02-0
Interest & Investment Income
--00.01
Other Non Operating Income (Expenses)
13.381.36-0.120.21
EBT Excluding Unusual Items
-2.71-0.73-2.41-1.42
Merger & Restructuring Charges
-1.48-1.6--
Gain (Loss) on Sale of Investments
---0.01-0.01
Gain (Loss) on Sale of Assets
----0.03
Other Unusual Items
-7.027.6-0.270.19
Pretax Income
-11.215.27-2.68-1.26
Earnings From Continuing Operations
-11.215.27-2.68-1.26
Minority Interest in Earnings
0.07---
Net Income
-11.145.27-2.68-1.26
Net Income to Common
-11.145.27-2.68-1.26
Shares Outstanding (Basic)
7222
Shares Outstanding (Diluted)
7422
Shares Change (YoY)
83.74%86.72%0.01%-
EPS (Basic)
-1.512.30-1.25-0.59
EPS (Diluted)
-1.511.34-1.25-0.59
Free Cash Flow
-17.16-2.98-2.09-2.34
Free Cash Flow Per Share
-2.33-0.74-0.97-1.09
Gross Margin
-24.26%-165.95%-9.63%
Operating Margin
-27807.14%-48.52%-383.83%-47.09%
Profit Margin
-19894.64%167.11%-453.44%-36.50%
Free Cash Flow Margin
-30641.07%-94.51%-352.55%-67.41%
EBITDA
-15.38-1.44-2.21-1.6
EBITDA Margin
--45.67%--46.13%
D&A For EBITDA
0.190.090.060.03
EBIT
-15.57-1.53-2.27-1.63
EBIT Margin
--48.52%--47.09%
Revenue as Reported
0.063.150.593.46
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q